Clinical Trials on Adenocarcinoma of Prostate

Total 40342 results

Case Comprehensive Cancer Center

Terminated

Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial

Adenocarcinoma of Prostate | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage III

United States
Dana-Farber Cancer Institute

Completed

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

Prostate Cancer | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage III

United States
Sir Mortimer B. Davis - Jewish General Hospital
Abbott

Recruiting

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

Adenocarcinoma of the Prostate

Canada
Virginia Commonwealth University

Completed

High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer

Adenocarcinoma of the Prostate

United States
University of California, Davis

Completed

Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate (CCRO025)

Adenocarcinoma of the Prostate

United States
Universitaire Ziekenhuizen KU Leuven
AZ Sint-Jan AV; General Hospital Groeninge; AZ Sint-Blasius Dendermonde

Recruiting

Prospective Prostate Cancer and Patient-reported Outcomes Registry (Prosquare)

Prostate Cancer | Adenocarcinoma of the Prostate | Locally Advanced Prostate Carcinoma | Locally Advanced Prostate Adenocarcinoma

Belgium
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Completed

Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery

Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
NanOlogy, LLC
US Biotest, Inc.

Completed

Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer

Adenocarcinoma of the Prostate

United States
Medical University of South Carolina
National Cancer Institute (NCI)

Completed

Docetaxel and Lycopene in Metastatic Prostate Cancer

Adenocarcinoma of the Prostate

United States
OHSU Knight Cancer Institute
Pfizer

Terminated

Pre-Prostatectomy Celecoxib or Placebo

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute

Completed

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Eli Lilly and Company

Completed

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

Adenocarcinoma of the Prostate

United States
Dana-Farber Cancer Institute

Completed

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Mary-Ellen Taplin, MD
Sanofi; Beth Israel Deaconess Medical Center; Genentech, Inc.; Duke University

Completed

Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

Prostate Cancer | Adenocarcinoma of the Prostate

United States
AstraZeneca

No longer available

Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer

Adenocarcinoma of the Prostate
University of Washington
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
John P. Fruehauf
Sanofi

Withdrawn

Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate (2007-5904)

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate
National Cancer Institute (NCI)

Completed

Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
National Cancer Institute (NCI)

Completed

Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate

Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
National Cancer Institute (NCI)

Completed

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Active, not recruiting

Radiation and Androgen Ablation for Prostate Cancer

Adenocarcinoma of the Prostate

United States
Brown University
AstraZeneca; The Miriam Hospital; Rhode Island Hospital

Terminated

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes (337)

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Georgetown... and other collaborators

Completed

Mifepristone (RU-486) in Androgen Independent Prostate Cancer

Prostate Cancer | Adenocarcinoma of Prostate

United States
National Cancer Institute (NCI)

Completed

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
University of Washington
National Cancer Institute (NCI)

Completed

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer (RAD1)

Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
Mayo Clinic

Completed

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
László Mangel
E-Group ICT Software Informatikai Zrt.

Recruiting

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

Metastatic Castration-resistant Prostate Cancer | Adenocarcinoma of the Prostate

Hungary
National Cancer Institute (NCI)

Terminated

Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Case Comprehensive Cancer Center

Completed

Enzalutamide in Patients With High-risk Prostate Cancer

Adenocarcinoma of the Prostate

United States
National Cancer Institute (NCI)

Terminated

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer

Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIB Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Terminated

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute

Completed

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of California, Irvine
Bristol-Myers Squibb

Completed

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
OHSU Knight Cancer Institute
Bristol-Myers Squibb; Oregon Health and Science University

Completed

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Millennium: The Takeda Oncology Company

Completed

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Terminated

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Burzynski Research Institute

Withdrawn

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Recurrent Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States

Clinical Trials on Adenocarcinoma of Prostate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations